检索结果-南通市图书馆

chinese Clinical Practice Guidelines for the Prevention and Treatment of Mother-to-Child Transmission of Hepatitis B Virus(Version 2024)

在线全文

学校读者我要写书评

暂无评论

Infectious Microbes & Diseases 2024年第3期6卷 108-116页

作者： Jinfeng Liu Qinglei Zeng Fanpu Ji Hong Ren Wenhong Zhang Lanjuan Li Yingren Zhao Infectious Diseases Physicians branch of chinese medical Doctor association chinese Society of Infectious Diseases of chinese medical association The First Affiliated Hospital of Xi’an Jiaotong University Xi’anChina Shaanxi Clinical medical Research Center of Infectious Diseases Xi’anChina The First Affiliated Hospital of Zhengzhou University ZhengzhouChina The Second Affiliated Hospital of Xi’an Jiaotong University Xi’anChina The Second Affiliated Hospital of Chongqing medical University ChongqingChina Huashan Hospital Fudan UniversityShanghaiChina State Key Laboratory for the Diagnosis and Treatment of Infectious Diseases The First Affiliated HospitalZhejiang University School of MedicineHangzhouChina 不详

The chinese Clinical Practice Guidelines for the prevention and treatment ofmother-to-child transmission of hepatitis B virus,developed by the chinese Society of Infectious Diseases of the chinese medical association in 2019,serves as a valuable reference for standardizing the process of preventing mother-to-child transmission in *** new evidence emerges,it is crucial that timely and regular updates are made to the clinical practice guidelines so as to optimize guidance for clinical practice and *** this end,the Infectious Disease Physician branch of chinese medical Doctor association and the chinese Society of Infectious Diseases of chinese medical association,in collaboration with multidisciplinary experts,have updated the guidelines based on the latest domestic and international research advancements and clinical practice,in order to provide guidance and reference for clinicians andmaternal and child healthcare workers.

关键词： guidelines hepatitis B virus mother-to-child transmission prevention treatment update

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

百乐眠胶囊治疗失眠症临床应用专家共识

中国中药杂志 2024年第20期 5635-5642页

作者： Expert Group of Psychosomatic medicine branch of China association of chinese medicine 中华中医药学会心身医学分会专家组

百乐眠胶囊作为适用于阴虚火旺型失眠症的中成药，目前被广泛应用于短期失眠症、慢性失眠症及卒中后失眠、失眠伴焦虑抑郁状态等心身疾病，并被多项共识/指南/路径推荐。该共识在专家访谈、问卷调研和百乐眠胶囊文献系统回顾的基础上，... 详细信息

百乐眠胶囊作为适用于阴虚火旺型失眠症的中成药，目前被广泛应用于短期失眠症、慢性失眠症及卒中后失眠、失眠伴焦虑抑郁状态等心身疾病，并被多项共识/指南/路径推荐。该共识在专家访谈、问卷调研和百乐眠胶囊文献系统回顾的基础上，遵循“循证为举，共识为主，经验为鉴”原则，总结现有最佳证据，充分结合专家经验以及患者偏好，基于百乐眠胶囊自身特点及临床实际，形成了百乐眠胶囊单用和联合西药用于治疗失眠症、慢性失眠症伴焦虑抑郁状态、特殊人群失眠症等7条推荐意见和12条共识建议。共识起草过程中，通过线上与线下相结合的征求意见方式，在全国范围内进行了征求意见和同行评议。该共识适用于各级医院的中医、西医和中西医结合医师，基层卫生服务机构的临床医师，为其合理使用百乐眠胶囊提供指导和参考。旨在指导和规范临床医生合理使用百乐眠胶囊，提高临床疗效和安全性。该共识已通过中华中医药学会审核发布，编号GS/CACM 329-2023。

关键词：百乐眠胶囊专家共识失眠症循证医学中医药

同方期刊数据库

Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer(2024 edition)

在线全文

学校读者我要写书评

暂无评论

Radiation medicine and Protection 2024年第2期5卷 59-67页

作者： Professional Committee of Radiation Oncology China Anti-Cancer association branch of Radiation Oncology chinese medical association branch of Radiation Oncology TreatmentPhysician chinese medical Doctor association Qingsong Pang Jun Wang Zhouguang Hui Wencheng Zhang 不详 Tianjin medical University Cancer Institute&Hospital Tianjin 300060China the Fourth Hospital of Hebei medical University Shijiazhuang 050011China National Cancer Center National Clinical Research Center for CancerCancer HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100021China Tianjin medical University Cancer Hospital China

Radiotherapy represents an essential treatment approach for esophageal *** recent years,immunotherapy combined with chemotherapy has become the first-line standard treatment for patients with advanced esophageal *** phase III studies on immunotherapy combined with radiotherapy for locally advanced esophageal cancer are currently *** evidence-based medical data are urgently needed to support the integration of immunotherapy and chemoradiotherapy as a new treatment strategy for patients with locally advanced esophageal *** consensus,formulated based on the latest study results,in-depth research,and thorough discussions,provides a comprehensive set of *** document extensively covers treatment strategies and evaluation methods for radiotherapy combined with immunotherapy across patients with operable esophageal cancer,inoperable locally advanced esophageal cancer,and advanced esophageal ***,common complications and radiation-related issues associated with radiotherapy combined with immunotherapy are discussed,serving as clinical *** expert group comprised members from the Professional Committee of Radiation Oncology,China Anti-Cancer association,the branch of Radiation Oncology,chinese medical association,and the branch of Radiation Oncology Treatment Physician,chinese medical Doctor association.

关键词： Esophageal squamous cell carcinoma Esophageal adenocarcinoma Immunotherapy Chemoradiotherapy Radiotherapy Expert consensus

chinese expert consensus on immunotherapy for advanced non-small cell lung cancer with oncogenic driver mutations(2023 edition)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

chinese medical Journal 2024年第9期137卷 1016-1018页

作者： The Society of Cancer Precision medicine of chinese Anti-Cancer association The Lung Cancer Expert Group of chinese medical association Publishing House Baohui Han Hua Zhong 不详 Department of Respiratory medicine Shanghai Chest HospitalSchool of MedicineShanghai JiaoTong UniversityShanghai 20030China Shanghai Chest Hospital Shanghai Jiao Tong University School of Medicine

Non-small cell lung cancer(NSCLC)with oncogenic driver mutations was previously deemed“forbidden territory”for immunotherapy.[1]With the continuous generation of evidence,immunotherapy is expected to bring hope for such NSCLC with oncogenic driver mutations after acquired tyrosine kinase inhibitor(TKI)***,given the intricate interplay between driven mutations,targeted therapy,and immune microenvironment,the efcacy of immunotherapy in advanced NSCLC patients with diverse oncogenic driver mutations remains a topic of ongoing *** this context,chinese Expert Consensus on Immunotherapy for Advanced NSCLC with Oncogenic Driver Mutations(2022 edition)wasrst launched in 2022 by the Society of Cancer Precision medicine of chinese Anti-Cancer association and the Lung Cancer Expert Group of chinese medical Journals,aiming to provide standardized treatment guidance for clinical practice.

关键词： immunotherapy cancer lung

Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors(2024)

在线全文

学校读者我要写书评

暂无评论

chinese Journal of Cancer Research 2024年第3期36卷 240-256页

作者： Zaiwei Song Dan Jiang Lingling Yu Yixuan Chen Daobin Zhou Yue Li Depei Wu Lingli Zhang Liyan Miao Jun Ma Jun Zhu Hongmei Jing Rongsheng Zhao the Steering Committee,the Consensus Panel and the Evidence Synthesis Group Evidence-based Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Hospital Pharmacy Professional Committee of chinese Pharmaceutical association(CPA) Division of Therapeutic Drug Monitoring of chinese Pharmacological Society(CPS) Expert Committee on Lymphoma of chinese Society of Clinical Oncology(CSCO) Expert Committee on Leukemia of chinese Society of Clinical Oncology(CSCO) Society of Integrative Cardio-Oncology of China Anti-Cancer association(CACA) chinese Society of Hematology of chinese medical association(CMA) Hospital Pharmacy Professional Committee of Cross-Straits medicine Exchange association(SMEA) Department of Pharmacy Peking University Third HospitalBeijing 100191China Institute for Drug Evaluation Peking University Health Science CenterBeijing 100191China Therapeutic Drug Monitoring and Clinical Toxicology Center Peking UniversityBeijing 100191China Department of Pharmacy Administration and Clinical Pharmacy School of Pharmaceutical SciencesPeking UniversityBeijing 100191China Department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing 100005China Department of Cardiology the First Affiliated HospitalHarbin Medical UniversityHarbin 150001China Department of Hematology the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Pharmacy Evidence-based Pharmacy CenterWest China Second HospitalSichuan UniversityChengdu 610041China Department of Pharmacy the First Affiliated Hospital of Soochow UniversitySuzhou 215006China Department of Hematology and Oncology Harbin Institute of Hematology and OncologyHarbin 150010China Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing) Department of LymphomaPeking University Cancer Hospital&InstituteBeijing 100142China Department of Hematology Peking University Third HospitalBeijing 100191China 不详

Bruton’s tyrosine kinase inhibitors(BTKis)have revolutionized the treatment of B-cell ***,safety issues related to the use of BTKis may hinder treatment continuity and further affect clinical efficacy.A comprehensive and systematic expert consensus from a pharmacological perspective is lacking for safety issues associated with BTKi treatment.A multidisciplinary consensus working group was established,comprising 35 members from the fields of hematology,cardiovascular disease,cardio-oncology,clinical pharmacy,and evidencebased *** evidence-based expert consensus was formulated using an evidence-based approach and the Delphi *** Joanna Briggs Institute Critical Appraisal(JBI)tool and Grading of Recommendations Assessment,Development,and Evaluation(GRADE)approach were used to rate the quality of evidence and grade the strength of recommendations,*** consensus provides practical recommendations for BTKis medication based on nine aspects within three domains,including the management of common adverse drug events such as bleeding,cardiovascular events,and hematological toxicity,as well as the management of drug-drug interactions and guidance for special *** multidisciplinary expert consensus could contribute to promoting a multi-dimensional,comprehensive and standardized management of BTKis.

关键词： Consensus BTK inhibitors safety adverse drug events drug-drug interactions

Stress Echocardiography for Chronic Coronary Syndrome:Clinical Practice Guidelines(2023)

在线全文

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2024年第5期21卷 475-505页

作者： Peng-Fei ZHANG Jia-Wei TIAN Tian-Gang ZHU Jue-Fei WU Xiao-Ping LENG Yi WANG Meng-Meng LI Xin-Hao LI Qian-Qian WANG Xiao-Peng FENG Jia-Yan LV Li-Xue YIN Yun ZHANG Mei ZHANG chinese Society of Echocardiography,Superficial Tissue and Vascular Group of chinese Society of Ultrasound in medicine,Ultrasound Professional Committee of chinese medicine Education association State Key Laboratory for Innovation and Transformation of Luobing Theory Key Laboratory of Cardiovascular Remodeling and Function ResearchChinese Ministry of EducationChinese National Health Commission and Chinese Academy of Medical SciencesDepartment of CardiologyQilu Hospital of Shandong UniversityJinanChina The Second Affiliated Hospital of Harbin medical University HaerbinChina Peking University People's Hospital BeijingChina Sichuan Province People's Hospital ChengduChina Nanfang Hospital Southern Medical UniversityGuangzhouChina Peking Union medical College Hospital Chinese Academy of Medical SciencesBeijingChina 不详

In the context of the People's Republic of China,coronary artery disease(CAD)presents a sig-nificant clinical challenge,with over 11.3 mil-lion patients ***,the diagnos-is of CAD has predominantly relied on invasive coronary angiography.[1]However,recent advances in clinical research have revealed a notable trend:a substantial 82% of patients subjected to such invas-ive diagnostics do not necessitate interventional therapy.

关键词： coronary clinical patients

chinese national clinical practice guideline on diagnosis and treatment of biliary tract cancers

在线全文

学校读者我要写书评

暂无评论

中华医学杂志(英文版) 2024年第19期137卷 2272-2293页

作者： Wang Xu’an Bai Yongrui Chai Ningli Li Yexiong Linghu Enqiang Wang Liwei Liu Yingbin Society of Hepato-pancreatobiliary Surgery of chinese Research Hospital association Society of Digestive Endoscopy of the chinese medical association chinese medical Journal Clinical Practice Guideline Collaborative Department of Biliary and Pancreatic Surgery Renji Hospital Shanghai Jiao Tong University School of Medicine State Key Laboratory of Systems medicine for Cancers Shanghai Cancer Institute Shanghai Key Laboratory for Cancer Systems Regulation and Clinical Translation Shanghai China Department of Radiation Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China Department of Gastroenterology and Hepatology the First Medical Center Chinese People’s Liberation Army General Hospital Beijing China State Key Laboratory of Molecular Oncology and Department of Radiation Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC) Beijing China State Key Laboratory of Oncogenes and Related Genes Shanghai Cancer Institute Department of Oncology Renji Hospital School of Medicine Shanghai Jiao Tong University Shanghai China

Background: Biliary tract carcinoma (BTC) is relatively rare and comprises a spectrum of invasive tumors arising from the biliary tree. The prognosis is extremely poor. The incidence of BTC is relatively high in Asian countries, and a high number of cases are diagnosed annually in China owing to the large population. Therefore, it is necessary to clarify the epidemiology and high-risk factors for BTC in China. The signs associated with BTC are complex, often require collaborative treatment from surgeons, endoscopists, oncologists, and radiation therapists. Thus, it is necessary to develop a comprehensive chinese guideline for ***: This clinical practice guideline (CPG) was developed following the process recommended by the World Health Organization. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess the certainty of evidence and make recommendations. The full CPG report was reviewed by external guideline methodologists and clinicians with no direct involvement in the development of this CPG. Two guideline reporting checklists have been adhered to: Appraisal of Guidelines for Research and Evaluation (AGREE) and Reporting Items for practice Guidelines in Healthcare (RIGHT).Results: The guideline development group, which comprised 85 multidisciplinary clinical experts across China. After a controversies conference, 17 clinical questions concerning the prevention, diagnosis, and treatment of BTC were proposed. Additionally, detailed descriptions of the surgical principles, perioperative management, chemotherapy, immunotherapy, targeted therapy, radiotherapy, and endoscopic management were ***: The guideline development group created a comprehensive chinese guideline for the diagnosis and treatment of BTC, covering various aspects of epidemiology, diagnosis, and treatment. The 17 clinical questions have important reference value for the management of BTC.

关键词： Biliary tract carcinoma Etiology Diagnosis Treatment Surgery

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

中医膏方临床应用与制备工艺规范

江苏中医药 2024年第11期56卷 1-7页

作者： Jiangsu Research Center for chinese medicine Development Jiangsu association of chinese medicine Jiangsu association of Integrative medicine 江苏省中医药发展研究中心江苏省中医药学会江苏省中西医结合学会

本文件为江苏省地方标准，编号：DB32/T 4870—2024。本文件由江苏省市场监督管理局2024年10月18日发布，2024年11月18日实施。本文件按照GB/T 1.1—2020《标准化工作导则第1部分：标准化文件的结构和起草规则》的规定起草。请注意本文... 详细信息

本文件为江苏省地方标准，编号：DB32/T 4870—2024。本文件由江苏省市场监督管理局2024年10月18日发布，2024年11月18日实施。本文件按照GB/T 1.1—2020《标准化工作导则第1部分：标准化文件的结构和起草规则》的规定起草。请注意本文件的某些内容可能涉及专利。本文件的发布机构不承担识别专利的责任。本文件由江苏省卫生健康委员会提出并组织实施，由江苏省卫生健康标准化技术委员会归口。本文件起草单位：江苏省中医药发展研究中心、江苏省中医药学会、江苏省中西医结合学会、江苏省中医院、江苏省中医药研究院、江苏中药产业研究院。本文件主要起草人：黄亚博、霍介格、罗兴洪、冯广清、刘沈林、申春悌、段金廒、沈洪、束雅春、倪文澎、沈夕坤、刘产明、史亚祥、虞鹤鸣、陈竞纬、花海兵、强雨叶。

关键词：标准化工作导则工艺规范专利市场监督管理局标准化文件江苏省

同方期刊数据库

综合医疗机构结核病发病高危人群的预防性治疗专家共识

在线全文

学校读者我要写书评

暂无评论

中华结核和呼吸杂志 2024年第10期47卷 933-945页

作者：中华医学会呼吸病学分会国家呼吸医学中心

针对发病高风险的结核潜伏感染者开展结核病预防性治疗, 是实现终结结核病流行全球战略目标的重要手段。作为结核病高负担国家, 我国既往的结核病防治更多侧重患者的主动发现和规范治疗, 尚未系统开展预防性治疗工作。综合医疗结构所涉...

针对发病高风险的结核潜伏感染者开展结核病预防性治疗, 是实现终结结核病流行全球战略目标的重要手段。作为结核病高负担国家, 我国既往的结核病防治更多侧重患者的主动发现和规范治疗, 尚未系统开展预防性治疗工作。综合医疗结构所涉及的结核病发病高危人群类型多、情况复杂, 开展结核病预防性治疗及其管理难度较大。为推动综合医疗机构结核病预防性治疗工作的实施, 中华医学会呼吸病学分会和国家呼吸医学中心牵头组织相关专家, 针对综合医疗机构结核病发病高危人群预防性治疗对象的界定、治疗时机、治疗方案等临床问题, 在循证医学基础上形成19条具有指导性的专家推荐意见, 供综合医疗机构的医务工作者在临床工作中参考和实践。

关键词：